AstraZeneca still waiting for the upside of MedImmune acquisition.
Pfizer: More Lipitor, fewer heart complications – A reanalysis of research data found a high dose of popular cholesterol pill Lipitor lowers risk of heart attack and stroke in some patients with both heart disease and kidney disease, the drug’s maker said Monday…more
Fred Hassan heads to Bausch & Lomb.
Novartis‘ Tekturna post-heart attack: Not a good idea. “Given these results, we are not currently recommending the use of this agent in addition to other inhibitors of the renin-angiotensin system in this specific patient population.”
eLearning Development – From modules to virtual preceptorships to virtual worlds, we’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
“I hate her uterus!” DTC, infertility, and a very effective on-line campaign. IncreaseYourChances.
JUST FOR FUN
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board